glp 1 going grey GLP-1 Receptor Agonists Linked to Lower AMD Risk in Obese, Nondiabetic Patients Effects of GLP-1 Medications on

They also reported that, based on these findings, additional prospective studies are needed to examine GLP1-RA use for pediatric MASLD and investigate the different mechanisms by which these medications affect the liver

Available from: www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023#:~:text=EMA%27s%20safety%20committee%20(PRAC)%20has,and%20lower%20part%20of%20the [Last accessed: December 31, 2023]

J.SungZ

467 Among patients with moderately to severely active UC, 40.6% of patients treated with tofacitinib (10 mg twice daily) for 8 weeks achieved significant remission

[DOI] [PubMed] [Google Scholar] 44.Yabe D, Nakamura J, Kaneto H, et al